News & Updates
Filter by Specialty:
Triplet regimen works against triple-negative breast cancer
Treatment with a novel combination of famitinib, camrelizumab, and nab-paclitaxel appears safe and effective in patients with advanced immunomodulatory triple-negative breast cancer (TNBC), as shown in the results of the phase II FUTURE-C-Plus trial.
Triplet regimen works against triple-negative breast cancer
08 Jul 2022
CVD prevention better with ACE inhibitor–statin combo than monotherapy
In patients with hypertension, combined treatment with angiotensin-converting enzyme (ACE) inhibitors plus statins reduces the risk of developing cardiovascular disease (CVD) at a greater magnitude as compared with ACE inhibitor monotherapy, a study has found.
CVD prevention better with ACE inhibitor–statin combo than monotherapy
08 Jul 2022
L-MOCA: Olaparib maintenance for ovarian cancer benefits Asians
Maintenance monotherapy with olaparib appears safe and effective in Asian patients with platinum-sensitive relapsed (PSR) ovarian cancer, regardless of their BRCA status, as shown in the results of the phase III, open-label, single-arm L-MOCA study.
L-MOCA: Olaparib maintenance for ovarian cancer benefits Asians
07 Jul 2022
RA patient’s perspective must be respected in treatment decisions, says study
Physician-reported measures on responses to tofacitinib and adalimumab treatments are higher than those reported by patients with rheumatoid arthritis (RA), according to a post hoc analysis of data from phase III and phase IIIb/IV trials.